$DSGN Up 29% Premarket! 🚀 🔹 Design Therapeutics just reported positive 4-week IV data from its RESTORE-FA trial in Friedreich ataxia 🔹 DT-216P2 showed dose-d

$DSGN Up 29% Premarket! 🚀 🔹 Design Therapeutics just reported positive 4-week IV data from its RESTORE-FA trial in Friedreich ataxia 🔹 DT-216P2 showed dose-dependent clinical improvements across mFARS, upright stability, and patient-reported fatigue 📈 🔹 Biomarker data also looked strong, with i…